Horizon Pharma Earnings Preview: Get Ahead of the Analysts

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Horizon Pharma (NASDAQ:HZNP) will report earnings before markets open on Friday, May 10th. Horizon Pharma, Inc., is a holding company. The Company, through its subsidiaries, develops and commercializes late-stage biopharmaceutical therapies for the treatment of pain and inflammation.

Here is your Cheat Sheet to Horizon Pharma Earnings:

Earnings Expectations: Analysts expect earnings of $-0.35 per share on revenues of $9.47 million.

Analyst Trends:

Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.45 to a loss $0.29. For the current year, the average estimate is a loss of $1.11, which is better than the estimate ninety days ago.

Earnings Trends:

Here’s how Horizon Pharma has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 0.00 0.00 2.38 6.93 19.63
Diluted EPS ($) -21.16 -12.56 -2.26

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 3.53 2.52 3.84 6.52 6.75
Diluted EPS ($) -3.898 -0.98 -0.68 -0.47 -0.3937

Past Performance:
Horizon Pharma has beat analyst estimates 2 times in the past four quarters. This is not consistent enough to get bullish yet.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business